EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
Michael T. McCabe(GlaxoSmithKline (United States)), Caretha L. Creasy, Charles F. McHugh(GlaxoSmithKline (United States)), Dashyant Dhanak(Wilmington University), Alan P. Graves(GlaxoSmithKline (United States)), Mark Mellinger(GlaxoSmithKline (United Kingdom)), Louis V. LaFrance(Johnson & Johnson (United States)), Xinrong Tian(GlaxoSmithKline (United Kingdom)), Sharad K. Verma(GlaxoSmithKline (United States)), Céline Duquenne(GlaxoSmithKline (United Kingdom)), Peter J. Tummino(Intarcia Therapeutics (United States)), Elsie Diaz(Johnson & Johnson (United States)), Heidi M. Ott(GlaxoSmithKline (United Kingdom)), Anthony Della Pietra(GlaxoSmithKline (United Kingdom)), Glenn S. Van Aller(GlaxoSmithKline (United Kingdom)), Ryan G. Kruger(Arysta LifeScience (France)), Yan Liu(Qingdao University), William H. Miller(Clinical Innovations (United States)), Gopinath Ganji(GlaxoSmithKline (United States)), Susan Korenchuk(GlaxoSmithKline (United Kingdom)), Christine Thompson(GlaxoSmithKline (United Kingdom)), Martín Brandt(SINTEF)
Cited by 1,797
Related Papers
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
|Nature|1999|1.9k
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k
The promise and peril of chemical probes
|Nature Chemical Biology|2015|848
Residence Time of Receptor−Ligand Complexes and Its Effect on Biological Function
|Biochemistry|2008|550